Cerebral malaria is a serious complication of infection with the malaria parasite, affecting approximately one in a thousand children in areas where malaria is common. Many of the patients die, and among those who survive, about a third have lasting cognitive and neurological disabilities, including epilepsy and learning disorders. A study published on March 6th in PLOS Pathogens shows that a known drug can prevent brain damage in a cerebral malaria mouse model and eliminate subsequent neurological deficits.
Infection with the malaria parasite elicits a strong immune response in the patient, and it is known that both parasite and host response contribute to the nervous system problems in cerebral malaria. Lena Serghides, from the Toronto General Research Institute, Canada, and colleagues are interested in modulating the host response to malaria infection, in addition to anti-parasite drugs, with the goal to improve outcomes in patients.
They focused on a drug called rosiglitazone (approved for patients with diabetes) which activates a molecule called PPARɣ and is known to have anti-inflammatory and anti-oxidant properties. Using a mouse model of cerebral malaria, they show that when they give rosiglitazone in addition to antimalarial drugs at the onset of cerebral malaria symptoms, mice are more likely to survive, and the survivors which had received rosiglitazone did not show the brain abnormalities or cognitive defects seen in surviving mice that had only received antimalarial drugs.
When they compared both groups of mice at the molecular level, they found that rosiglitazone protects the integrity of the blood-brain-barrier and increases the level of anti-oxidant enzymes and of neuroprotective factors in the brain. One of the latter, called BDNF (for brain-derived neurotropic factor), was also increased in the blood of adult human patients with uncomplicated malaria who had participated in a clinical trial and received antimalarial drugs plus rosiglitazone, compared with other trial participants who had only taken antimalarials.
"Our results demonstrate that rosiglitazone adjunctive therapy resulted in increased survival and protection from long-term cognitive impairments in a mouse model of cerebral malaria", the authors say, "And the clinical trial data suggests that this approved drug, which has an excellent safety profile when taken for limited periods, might also induce such putative protective mechanisms in humans". They conclude that "in view of these results, testing rosiglitazone in patients with cerebral malaria is warranted."
Financial support for this work provided by Grand Challenge Canada Stars in Global Health (LS), Defense Advanced Research Projects Agency grant 58217-LS-DRP (KCK), Canadian Institutes of Health Research MOP-13721 and 244701 (KCK), Ontario HIV Treatment Network Junior Investigator Development Award (LS), and the Canada Research Chair (KCK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
I have read the journal's policy and have the following conflicts: The University Health Network holds intellectual property pertaining to the use of PPARc agonists for the treatment of severe malaria. The authors have no other financial interests related to this work. This does not alter our adherence to all PLOS Pathogens policies on sharing data and materials.
© 2014 Serghides et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
IN YOUR COVERAGE PLEASE PROVIDE THIS LINK TO THE FREELY AVAILABLE PAPER:
Authors of this research article:
Lena Serghides, University Health Network, Canada
Chloe R. McDonald, University of Toronto, Canada
Ziyue Lu, University Health Network, Canada
Miriam Friedel, Hospital for Sick Children, Canada
Cheryl Cui, University of Toronto, Canada
Keith T. Ho, University of Toronto, Canada
Howard T.J. Mount, University of Toronto, Canada
John G. Sled, Hospital for Sick Children, Canada
Kevin C. Kain, University Health Network, Canada